Second Genome

Overview

Second Genome is a drug discovery company that mines the human microbiome's functional genomic diversity to identify and develop novel therapeutics. Rather than transplanting microbes, the company identifies bioactive proteins and small molecules naturally produced by gut bacteria and develops them as conventional pharmaceutical drugs. Its proprietary Microbiome Discovery Engine uses metagenomic sequencing of large clinical cohorts combined with machine learning to identify microbial gene products associated with disease states, then validates and optimizes lead candidates through medicinal chemistry. Pharmaceutical partners and Second Genome's internal pipeline teams use the Microbiome Discovery Engine to identify drug candidates in inflammatory bowel disease, metabolic syndrome, fatty liver disease, and oncology — areas where microbiome dysbiosis plays a mechanistic role. The company has generated multiple clinical and preclinical programs, including SG-3-1002 for ulcerative colitis and SGM-1019 for NASH. Partnerships with major pharmaceutical companies including Takeda and Pfizer have included multi-million dollar licensing arrangements. Second Genome's differentiation lies in its drug-centric view of the microbiome: by developing isolated, characterized molecules rather than living bacterial consortia, the company avoids the manufacturing complexity, regulatory uncertainty, and patient acceptance challenges associated with live biotherapeutic products. Its metagenomics-to-drug pipeline converts the chemical diversity of the human microbiome — estimated to encode hundreds of thousands of novel enzymes and peptides — into a systematic source of drug leads with known mechanisms of action. This approach positions microbiome science within familiar pharmaceutical drug development frameworks.

Key Features

Pros & Cons

Use Cases